ArticleFrontiers in molecular biosciences2026
TRIM2 suppresses prostate cancer progression by promoting ubiquitin-mediated degradation of DTNBP1.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective/Background: Prostate cancer is the most commonly diagnosed malignancy in men worldwide, with high mortality rates and frequent metastasis at initial diagnosis, underscoring the need to elucidate its molecular mechanisms. TRIM2, an E3 ubiquitin ligase, plays critical roles in several cancers, but its function in prostate cancer remains unclear. This study aimed to investigate the expression, biological function, and clinical significance of TRIM2 in PCa progression. Methods: TRIM2 expression was analyzed using TCGA, GTEx, and GEO datasets, and validated in PCa and BPH tissues via qRT-PCR, western blot, and immunohistochemistry. Functional assays (CCK-8, wound healing, Transwell, flow cytometry) were performed in DU145 and PC-3 cells with TRIM2 overexpression or knockdown, and xenograft models assessed tumorigenicity in vivo. Proteomic sequencing combined with database prediction (UbiBrowser, BioGRID) identified DTNBP1 as a downstream substrate, confirmed by co-immunoprecipitation, ubiquitination assays, and cycloheximide chase. Drug sensitivity was evaluated using the GDSC database and molecular docking. Results: TRIM2 was significantly downregulated in PCa tissues, with the lowest levels observed in advanced and castration-resistant cases, and its reduced expression independently predicted worse progression-free interval. ROC analysis demonstrated that TRIM2 effectively discriminated localized from advanced/CRPC disease. TRIM2 overexpression significantly suppressed malignant behaviors Conclusion: Our findings establish the TRIM2-DTNBP1 axis as a key driver of PCa progression and position TRIM2 as a promising prognostic biomarker and a potential predictive indicator for guiding molecularly targeted therapies in advanced PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.